Lai Wang
Chief Tech/Sci/R&D Officer bij BEIGENE, LTD.
Vermogen: 20 M $ op 31-03-2024
Profiel
Mr. Lai Wang is Global Head-Research & Development bij BeiGene Ltd.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
BEIGENE LTD
0.13% | 26-06-2023 | 1 658 215 ( 0.13% ) | 20 M $ | 31-03-2024 |
Actieve functies van Lai Wang
| Bedrijven | Functie | Begin |
|---|---|---|
| BEIGENE, LTD. | Chief Tech/Sci/R&D Officer | 01-04-2021 |
Eerdere bekende functies van Lai Wang
| Bedrijven | Functie | Einde |
|---|---|---|
Joyant Pharmaceuticals, Inc.
 Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Corporate Officer/Principal | - |
Opleiding van Lai Wang
| Fudan University | Undergraduate Degree |
| University of Texas Health Science Center at Houston | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BEIGENE, LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Joyant Pharmaceuticals, Inc.
Joyant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Joyant Pharmaceuticals is a Dallas-based drug discovery company focused on the development of small molecule therapeutics for cancer. Their core competencies include chemical synthesis biochemistry, cell biology, and pharmacology. The focus of its company is on the development of unique chemical entities that operate by new cellular mechanisms. Its understanding of the molecular events that control the growth, replication, and apoptosis of human cells is becoming increasingly sophisticated. They intend to translate new knowledge of such pathways, and their misregulation in disease, into signaling-based targeted therapeutics. | Health Technology |
